Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.

ABSTRACT: Drug-induced thrombotic microangiopathy (DITMA) represents 10%-13% of all thrombotic microangiopathy (TMA) cases and about 20%-30% of secondary TMAs, just behind pregnancy-related and infection-related forms. Although the list of drugs potentially involved as causative for TMA are rapidly increasing, the scientific literature on DITMA is quite scarce (mostly as individual case reports or little case series), leading to poor knowledge of pathophysiological mechanisms and clinical management. In this review, we focused on these critical aspects regarding DITMA. We provided an updated list of TMA-associated drugs that we selected from a scientific literature review, including only those drugs with a definite or probable causal association with TMA. The list of drugs is heterogeneous and could

SUBMITTER: Mazzierli T 

PROVIDER: S-EPMC9868185 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature